NASDAQ:BBOT BridgeBio Oncology Therapeutics Q2 2026 Earnings Results & Report $2.90 -0.05 (-1.69%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$2.90 +0.00 (+0.17%) As of 10/14/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. BridgeBio Oncology Therapeutics reported Q2 2026 earnings on August 11, 2026. The company reported EPS of -$705.20. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 11, 2026TimeAfter Market ClosesConference Call4:00 PM ET BridgeBio Oncology Therapeutics EPS ResultsActual EPS-$705.20Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABridgeBio Oncology Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) BridgeBio Oncology Therapeutics Q2 2026 Earnings FAQ Did BridgeBio Oncology Therapeutics beat earnings estimates for Q2 2026? BridgeBio Oncology Therapeutics (NASDAQ:BBOT) reported earnings of -$705.20 per share for Q2 2026. The report was announced on Tuesday, August 11, 2026. BridgeBio Oncology Therapeutics Earnings HeadlinesBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 12 at 4:05 PM | globenewswire.comBridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Stock Has Average Price Target of $22.88 According to AnalystsOctober 8, 2026 | americanbankingnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely. | Altimetry (Ad)Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), Ascendis Pharma (ASND) and BridgeBio Oncology Therapeutics (BBOT)September 16, 2026 | theglobeandmail.comBridgeBio Oncology Therapeutics consensus price target cut by 13.05% to $22.55September 15, 2026 | msn.comBridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS PlaybookSeptember 12, 2026 | finance.yahoo.comSee More BridgeBio Oncology Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BridgeBio Oncology Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BridgeBio Oncology Therapeutics and other key companies, straight to your email. Email Address About BridgeBio Oncology TherapeuticsBridgeBio Oncology Therapeutics (NASDAQ:BBOT). is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company seeks to address cancer-causing mutations with targeted therapies designed to selectively interfere with disease-driving proteins and pathways. Its lead program, BBO-8520, is an investigational small-molecule inhibitor targeting KRAS G12C, a mutation found in several solid tumors, including non-small cell lung cancer, colorectal cancer and pancreatic cancer. The company is also developing additional precision-oncology programs, including therapies directed at other genetically validated cancer targets. BridgeBio Oncology Therapeutics was established within the BridgeBio Pharma ecosystem and is based in the United States. Its drug candidates remain in clinical development and are not approved for commercial use. The company’s programs are intended for patients whose tumors are identified through molecular or genetic testing.View BridgeBio Oncology Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
